Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Blood (2019) 134 (Supplement_1): 754.

https://doi.org/10.1182/blood-2019-126064

Published: 2019

Journal Articles

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Mark Blaine Geyer, MD, Ellen K. Ritchie, MD, Arati V. Rao, MD, M. Isabella Cazacu, Shreya Vemuri, Martin S. Tallman, MD, Dan Douer, MD, Jae H. Park, MD

Blood (2018) 132 (Supplement 1): 4013.

https://doi.org/10.1182/blood-2018-99-115486

Published: 2018

Journal Articles

A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

Jae H. Park, MD, Ellen K. Ritchie, MD, Arati V. Rao, Sean Devlin, PhD, Meier Hsu, MS, Talal T Khawaja, B.S., Bridget A O'Donnell, B.S., Maria I Cazacu, B.S., Diane M Stopka, MS, Martin S. Tallman, MD, Dan Douer, MD

Blood (2016) 128 (22): 1629.

https://doi.org/10.1182/blood.V128.22.1629.1629

Published: 2016

Journal Articles

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Jeffrey P. Sharman, Gilles A. Salles, Wojciech Jurczak, Jeffrey Jones, Carolyn J. Owen, MD MDes(UK), FRCPC, Veerendra Munugalavadla, Lyndah K. Dreiling, Yuanyuan Xiao, Arati V. Rao, Ian W. Flinn, MD PhD, Susan M. O'Brien, MD

Blood (2016) 128 (22): 5583.

https://doi.org/10.1182/blood.V128.22.5583.5583

Published: 2016

Journal Articles

Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis

Richard R. Furman, Michael Hallek, Jeffrey P. Sharman, Peter Hillmen, Andrew D. Zelenetz, Ian W. Flinn, MD PhD, Wojciech Jurczak, Veerendra Munugalavadla, Yuanyuan Xiao, Lianqing Zheng, Arati V. Rao, Lyndah K. Dreiling, Gilles A. Salles, Susan M. O'Brien, MD

Blood (2016) 128 (22): 5588.

https://doi.org/10.1182/blood.V128.22.5588.5588

Published: 2016

Journal Articles

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

Carter Thomas Davis, MD, Arati V. Rao, MD, Eross Guadalupe, Dale J. Christensen, PhD, J. Brice Weinberg, MD

Blood (2016) 128 (22): 5126.

https://doi.org/10.1182/blood.V128.22.5126.5126

Published: 2016

Journal Articles

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Cristina Gasparetto, MD, Michael Green, MD, Anandgopal Srinivasan, MDcal Student, Yubin Kang, MD, David A. Rizzieri, MD, Carlos Decastro, MD, Louis F. Diehl, MD, Anne Beaven, MD, Zighuo Li, PhD, Arati V. Rao, MD, Anderson Garrett, Sascha Tuchman, MD, Gwynn D. Long, MD

Blood (2015) 126 (23): 1857.

https://doi.org/10.1182/blood.V126.23.1857.1857

Published: 2015

Journal Articles

Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Eunice S. Wang, MD, Gary J Schiller, MD, Leonard T. Heffner, MD, Wendy Stock, MD, Arati V. Rao, MD, Gail J. Roboz, MD, Peter Westervelt, MD PhD, Matthew J. Wieduwilt, MD PhD, Jay Yang, MD, Lucy Prasad, Karen Segarini, Stuart L. Goldberg, MD

Blood (2015) 126 (23): 2491.

https://doi.org/10.1182/blood.V126.23.2491.2491

Published: 2015

Journal Articles

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Blood (2015) 126 (23): 2536.

https://doi.org/10.1182/blood.V126.23.2536.2536

Published: 2015

Journal Articles

Acute and Chronic Lymphocytic Leukemia Induces Exhaustion and Suppresses Metabolic Reprogramming in T Cell Activation

Peter J. Siska, MD, J. Brice Weinberg, MD, Arati V. Rao, MD, James R. Bain, PhD, Michael J. Muehlbauer, PhD, Tingyu Liu, Jeffrey Rathmell, PhD

Blood (2014) 124 (21): 4121.

https://doi.org/10.1182/blood.V124.21.4121.4121

Published: 2014

Journal Articles

Exome Sequencing Reveals The Genetic Landscape Of Rare Atypical e6a2 CML

Arati V. Rao, MD, Yuri D. Fedoriw, MD, Kristy L. Richards, MD PhD, Zhen Sun, MS, Cassandra L Love, MS, Sandeep Dave, MD

Blood (2013) 122 (21): 3995.

https://doi.org/10.1182/blood.V122.21.3995.3995

Published: 2013

Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Blood (2013) 122 (21): 1548.

https://doi.org/10.1182/blood.V122.21.1548.1548

Published: 2013

Journal Articles

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Tod A. Morris, MD, David A. Rizzieri, MD, Carlos M de Castro, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Anand S. Lagoo, MD, PhD, Joseph O. Moore, MD, Arati V Rao, MD

Blood (2011) 118 (21): 3590.

https://doi.org/10.1182/blood.V118.21.3590.3590

Published: 2011

Journal Articles

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

Arati V Rao, MD, David A. Rizzieri, MD, Louis F. Diehl, MD, Jon P. Gockerman, MD, Mitchell E. Horwitz, MD, Joseph O. Moore, MD, Natalie Sacarakis, Carlos Manuel de Castro, III, MD

Blood (2011) 118 (21): 5021.

https://doi.org/10.1182/blood.V118.21.5021.5021

Published: 2011

Journal Articles

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Carlos Manuel de Castro, III, MD, Donna Adams, RN, Arati V Rao, MD, Joseph O. Moore, MD, Jon P. Gockerman, MD, Louis F. Diehl, MD, Anne W Beaven, MD, Julie Warzecho, RN, David A. Rizzieri, MD

Blood (2011) 118 (21): 5029.

https://doi.org/10.1182/blood.V118.21.5029.5029

Published: 2011

Journal Articles

Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.

Arati V Rao, Sascha A Tuchman, Anil Potti, David A. Rizzieri, MD, Hiroyuki Mano, Ruud Delwel, PhD, Peter Valk, B. Lowenberg, MD

Blood (2008) 112 (11): 2252.

https://doi.org/10.1182/blood.V112.11.2252.2252

Published: 2008

Journal Articles

Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.

Arati V. Rao, MD, David A. Rizzieri, MD, Joseph O. Moore, MD, Carlos DeCastro, MD, Louis F. Diehl, MD, Amy P. Abernethy, MD, PhD, McLean Jordan, RN, Patty Davis, RN, Emily Edmonds, RN, Jon P. Gockerman, MD

Blood (2005) 106 (11): 4610.

https://doi.org/10.1182/blood.V106.11.4610.4610

Published: 2005

Journal Articles

Dose Dense, High Intensity Therapy in Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia Using Gemtuzumab Ozogamicin (Mylotarg™) and High Dose Cytarabine (HiDAC).

Arati V. Rao, M.D., David A. Rizzieri, M.D., Joseph O. Moore, M.D., Carlos DeCastro, M.D., Amy P. Abernethy, M.D., McLean Jordan, Patty Davis, Emily Edmonds, Jon P. Gockerman, M.D.

Blood (2004) 104 (11): 4516.

https://doi.org/10.1182/blood.V104.11.4516.4516

Published: 2004

NARROW

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase Is Safe and Results in High Rates of MRD Negativity in Adults Ages 18-60 with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial

Temporal Profiles of Lymphocyte Subsets and the Correlation with Infectious Events in Idelalisib-Treated Patients

Evaluation of Immune Mechanisms to Understand Idelalislib-Associated Diarrhea-Colitis

Fingolimod Is Cytotoxic in Acute Myeloid Leukemia Independent of Additional Chemotherapeutic Agents

A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.

Plasma Vincristine Levels Are 100-Fold Higher with Marqibo® (Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Long-Term Follow-up Results: A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed c-Kit Positive Acute Myeloid Leukemia (AML)

Acute and Chronic Lymphocytic Leukemia Induces Exhaustion and Suppresses Metabolic Reprogramming in T Cell Activation

Exome Sequencing Reveals The Genetic Landscape Of Rare Atypical e6a2 CML

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Re-Induction Therapy Decisions Based on Day 14 Bone Marrow Biopsy in Acute Myeloid Leukemia,

Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience

A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS Int-2 or High) Myelodysplastic Syndrome

Gene Expression Profiles with Signatures of Tumor Biology and Chemotherapy Sensitivity May Provide a Novel Approach to Maximize Response to Induction Therapy in Patients with Acute Myeloid Leukemia.

Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotarg™) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.

Dose Dense, High Intensity Therapy in Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia Using Gemtuzumab Ozogamicin (Mylotarg™) and High Dose Cytarabine (HiDAC).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only